Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 2/2017

01-02-2017 | Neurology of Systemic Diseases (J Biller, Section Editor)

Neurological Complications of the Leukemias Across the Ages

Authors: Stephanie Berg, Sucha Nand

Published in: Current Neurology and Neuroscience Reports | Issue 2/2017

Login to get access

Abstract

Purpose of Review

Acute and chronic leukemias are heterogeneous diseases and can affect any part of the body upon initial discovery. Understanding the sequela of systemic involvement is key for proper diagnosis and treatment.

Recent Findings

Over the decades, new research has emerged regarding neurological complications of the myeloid or lymphoid leukemias. Central nervous system involvement usually confers a poor prognosis and requires emergent treatment. Standard of care still involves systemic therapy, intrathecal administration of chemotherapeutic agents, and cranial radiation. Treatment-related side effects can occur and need to be recognized by any practitioner involved with patient care.

Summary

It is imperative to understand neurologic complications from leukemia to prevent delays and initiate necessary treatment to maintain neurologic and cognitive function.
Literature
1.
2.
Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukemia. Lancet Oncol. 2008;9:257068.CrossRef
3.
Morra E et al. The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Cancer. 1993;72(2):439–45.CrossRefPubMed
4.
Aoki J, Ishiyama K, Taniguchi S, Fukuda T, Takami A, et al. Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement. Biol Blood Marrow Transplant. 2014;20(12):2029–33.CrossRefPubMed
5.
Bar M, Tong W, Othus M, Loeb KR, Estey EH. Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(3):546–51.CrossRefPubMed
6.
Walker GV, Shihadeh F, Kantarjian H, et al. Comprehensive craniospinal radiation for controlling central nervous system leukemia. Int J Radiat Oncol Biol Phys. 2014;90(5):1119–25.CrossRefPubMedPubMedCentral
7.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMed
8.
• Shihadeh F, Reed V, Faderl S, Medeiros LJ, Mazloom A, Hadziahmetovic M, et al. Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. Cancer. 2012;118(1):112. Shihadeh et al. provided a thorough review of important cytogenetic profiles characteristic of AML patients diagnosed with CNS disease. Cytogenetics play a vital role in determining prognosis for all patients diagnosed with AML.CrossRefPubMed
9.
Ferro A et al. Cranial irradiation in adults diagnosed with acute myelogenous leukemia presenting with hyperleukocytosis and neurologic dysfunction. Leuk Lymphoma. 2014;55(1):105–9.CrossRefPubMed
10.
•• Rollig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125(21):3246–52. This was a good review regarding hyperleukocytosis in AML patients with important treatment options and pathophysiology. CrossRefPubMed
11.
Porcu P et al. Therapeutic leukapheresis in hyperleucocytic leukemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol. 1997;98(2):433–6.CrossRefPubMed
12.
Pastore F, Pastore A, Whittmann G, Hiddlemann W, Spiekermann K. The role of therapeutic leukaphresis in hyperleukocytotic AML. PLoS ONE. 2014;9(4):e95062.CrossRefPubMedPubMedCentral
13.
Saito T, Koyama T, Nagata K, et al. Anticoagulant effects of retinoic acids on leukemia cells. Blood. 1996;87:657–65.PubMed
14.
Lawrence JB, Yomtovian RA, Hammons T, Masarik SR, Chongkolwatana V, Creger RJ, et al. Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leuk Lymphoma. 2001;41(1–2):67–76.CrossRefPubMed
15.
Avni B, Koren-Michowitz M. Myeloid sarcoma: current approach and therapeutic options. Adv Hematol. 2011;2:309–16.CrossRef
16.
Nayak L, Pentsova E, Batchelor TT, Primary CNS. Lymphoma and neurologic complications of hematologic malignancies. Continuum. 2015;21(2):355–72.PubMed
17.
Cervantes GM, Cayci Z. Intracranial CNS manifestations of myeloid sarcoma in patients with acute myeloid leukemia: review of the literature and three case reports from the authors institution. J Clin Med. 2015;4(5):1102–12.CrossRefPubMedPubMedCentral
18.
Bakst R, Wolden S, Yahalorn J. Radiation therapy for chloroma. Int J Radiat Oncol Biol Phys. 2012;82(5):1816–22.CrossRefPubMed
19.
Thomas X, Boiron JM, Huguet F, Dombert H, Bradstock K, Vet N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075–86.CrossRefPubMed
20.
• Del Principe ML, Maurillo L, Buccisano F, et al. Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy. Mediterr J Hematol Infect Dis. 2014;6(1):e2014075. Del Principe et al. reviewed many cases from European data regarding ALL and CNS involvement citing important diagnostic tests with corresponding literature citations. CrossRefPubMedPubMedCentral
21.
Thomas X, Le QH. Central nervous system involvement in adult acute lymphoblastic leukemia. Hematology. 2008;13:293–302.CrossRefPubMed
22.
Lazarus HM et al. Central Nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E 2993. Blood. 2006;108(2):465–72.CrossRefPubMedPubMedCentral
23.
Surapaneni UR, Cortes JE, Thomas D, et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002;94(3):773–9.CrossRefPubMed
24.
Wellwood J, Taylor K. Central nervous system prophylaxis in haematological malignancies. Intern Med J. 2001;32:252–8.CrossRef
25.
Altintas A, Cil TT, Kilinc I, Kaplan MA, Ayyildiz O. Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. J Neurooncol. 2007;84(1):103–5.CrossRefPubMed
26.
Sancho JM, Ribera JM, Oriol A, et al. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia. Cancer. 2006;106:2540–6.CrossRefPubMed
27.
28.
Reman O, Pigneux A, Huguet F, Vey N, Thomas X, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. Leuk Res. 2008;32:1741–50.CrossRefPubMed
29.
Cortes J, O’Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995;86(6):2091–7.PubMed
30.
Pui C-H, Mahmoud HH, River GK, et al: Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92: 411–15.
31.
Kantarjian HM, Obrien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547–61.CrossRefPubMed
32.
Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow up results of Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788–801.CrossRefPubMed
33.
Jabbour E, O’Brien S, Kantarjian H, Manero GG, Ferrajoli A, Ravandi F, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;109(8):3214–8.CrossRefPubMed
34.
Demopoulos A, DeAngelis LM. Neurologic complications of leukemia. Curr Opin Neurol. 2002;15:691–9.CrossRefPubMed
35.
LeClerc JM, Billett AL, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol. 2002;20:237–46.CrossRefPubMed
36.
Chamberlin MC. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for treatment of leptomeningeal metastases: a retrospective case series. J Neurooncol. 2012;109(1):143–8. doi:10.​1007/​s11060-012-0880-x.CrossRef
37.
Khan et al. Neurologic morbidity and quality of life in survivors of childhood acute lymphoblastic leukemia: a prospective cross-sectional study. J Cancer Surviv. 2014;8(4):688–96.CrossRefPubMedPubMedCentral
38.
39.
40.
Moazzam AA, Drappatz J, Kim TY, Kesari S. Chronic lymphocytic leukemia with central nervous system involvement: report of two cases with a comprehensive literature review. J Neurooncol. 2012;106:185–200.CrossRefPubMed
41.
Hanse MC, Van Veer MB, van Lom K, Van den Bent MJ. Incidence of central nervous system involvement in chronic lymphocytic leukemia and outcome to treatment. J Neurol. 2008;255(6):828–30.CrossRefPubMed
42.
Soni A, Paluri R, Deal T, Peker D. Extramedullary involvement by chronic myelogeneous leukemia in five patients with unusual clinicopathologic features: a review of the effectiveness of tyrosine kinase inhibitors. Clin Med Res. 2016;8(6):480–5.CrossRef
43.
Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21(2):340–50.CrossRefPubMed
44.
Grace RF, Dahlberg SE, Neuberg D, Sallan ES, Connors JM, Neufeld EJ, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia on Dana-Farber Cancer Institute consortium protocols. Br J Hematol. 2011;152:452–9.CrossRef
45.
Ranta S, Tuckuviene R, Mäkipernaa A, Albertsen BK, Frisk T, Tedgård U, et al. Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia—a multicentre study from the Nordic Society of Paediatric Haematology and Oncology. Br J Haematol. 2015;168(4):547–52. doi:10.​1111/​bjh.​13162.CrossRefPubMed
46.
Vavricka SR, Walter RB, Irani S, Halter J, Schanz U. Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion. Ann Hematol. 2003;82:570–3.CrossRefPubMed
47.
Williams AM, Zent CS, Janelsins MC. What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. Br J Haematol. 2016;174:835–46.CrossRefPubMed
48.
Dutta V. Chemotherapy, neurotoxicity, and cognitive changes in breast cancer. J Cancer Res Ther. 2011;7:264–9.CrossRefPubMed
49.
Janelsin MC, Kesler SR, Ahles TA, et al. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26:102–13.CrossRef
50.
Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children’s cancer group studies for childhood ALL 1983–2002: a Children’s Oncology Group Report. Leukemia. 2010;24:285–97.CrossRefPubMed
51.
Metadata
Title
Neurological Complications of the Leukemias Across the Ages
Authors
Stephanie Berg
Sucha Nand
Publication date
01-02-2017
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 2/2017
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-017-0726-1

Other articles of this Issue 2/2017

Current Neurology and Neuroscience Reports 2/2017 Go to the issue

Pediatric Neurology (WE Kaufmann, Section Editor)

Transcranial Magnetic and Direct Current Stimulation in Children

Headache (RB Halker, Section Editor)

A Clinical Approach to Addressing Diet with Migraine Patients

Pediatric Neurology (WE Kaufmann, Section Editor)

Epileptic Encephalopathies—Clinical Syndromes and Pathophysiological Concepts

Neuro-Oncology (LE Abrey, Section Editor)

New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M

Neurology of Systemic Diseases (J Biller, Section Editor)

Stroke Chameleons and Stroke Mimics in the Emergency Department

Infection (J Halperin, Section Editor)

Emerging Causes of Arbovirus Encephalitis in North America: Powassan, Chikungunya, and Zika Viruses